Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 11 | 2015 | 1187 | 1.090 |
Why?
|
| Organoids | 2 | 2022 | 36 | 0.970 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2023 | 29 | 0.870 |
Why?
|
| Asthma | 2 | 2024 | 282 | 0.860 |
Why?
|
| Metformin | 1 | 2023 | 63 | 0.820 |
Why?
|
| Lung | 3 | 2022 | 507 | 0.730 |
Why?
|
| Aspirin | 2 | 2011 | 111 | 0.660 |
Why?
|
| Cystic Fibrosis | 1 | 2021 | 151 | 0.640 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 281 | 0.590 |
Why?
|
| Neoadjuvant Therapy | 3 | 2013 | 119 | 0.450 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2011 | 1000 | 0.360 |
Why?
|
| Diphosphonates | 1 | 2010 | 90 | 0.340 |
Why?
|
| Imidazoles | 1 | 2010 | 128 | 0.340 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 235 | 0.330 |
Why?
|
| Protein Phosphatase 1 | 1 | 2009 | 7 | 0.330 |
Why?
|
| Adolescent | 5 | 2024 | 6459 | 0.330 |
Why?
|
| Losartan | 1 | 2009 | 27 | 0.330 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 48 | 0.330 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2009 | 49 | 0.330 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 122 | 0.320 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2009 | 43 | 0.320 |
Why?
|
| Isoenzymes | 1 | 2009 | 168 | 0.310 |
Why?
|
| MAP Kinase Signaling System | 1 | 2009 | 118 | 0.310 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 508 | 0.300 |
Why?
|
| Child | 4 | 2024 | 6862 | 0.290 |
Why?
|
| Humans | 20 | 2024 | 50201 | 0.260 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 1176 | 0.250 |
Why?
|
| Female | 15 | 2024 | 26829 | 0.210 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2023 | 100 | 0.210 |
Why?
|
| Preoperative Care | 1 | 2024 | 167 | 0.210 |
Why?
|
| Home Care Services | 1 | 2023 | 72 | 0.200 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2022 | 4 | 0.200 |
Why?
|
| Medicaid | 1 | 2024 | 256 | 0.200 |
Why?
|
| Young Adult | 4 | 2023 | 4052 | 0.190 |
Why?
|
| Body Height | 1 | 2021 | 65 | 0.190 |
Why?
|
| Mass Screening | 1 | 2024 | 348 | 0.180 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 290 | 0.180 |
Why?
|
| Anthracyclines | 2 | 2011 | 29 | 0.180 |
Why?
|
| Nutritional Status | 1 | 2021 | 136 | 0.180 |
Why?
|
| Disease Progression | 1 | 2023 | 821 | 0.180 |
Why?
|
| Incidence | 2 | 2011 | 1000 | 0.150 |
Why?
|
| Child, Preschool | 2 | 2024 | 3896 | 0.140 |
Why?
|
| Retrospective Studies | 4 | 2024 | 6190 | 0.130 |
Why?
|
| Adult | 5 | 2023 | 13486 | 0.130 |
Why?
|
| Multiple Myeloma | 1 | 2010 | 2934 | 0.130 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2015 | 23 | 0.120 |
Why?
|
| Cardiomyopathies | 1 | 2015 | 116 | 0.110 |
Why?
|
| Receptors, Progesterone | 2 | 2013 | 63 | 0.110 |
Why?
|
| Receptor, erbB-2 | 2 | 2013 | 74 | 0.110 |
Why?
|
| Receptors, Estrogen | 2 | 2013 | 130 | 0.110 |
Why?
|
| Axilla | 1 | 2013 | 91 | 0.110 |
Why?
|
| Male | 5 | 2024 | 25572 | 0.100 |
Why?
|
| Prognosis | 3 | 2015 | 1963 | 0.100 |
Why?
|
| Heart | 1 | 2015 | 336 | 0.100 |
Why?
|
| Phenotype | 1 | 2015 | 732 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 226 | 0.100 |
Why?
|
| Survival Rate | 2 | 2013 | 906 | 0.100 |
Why?
|
| Dacarbazine | 1 | 2011 | 8 | 0.100 |
Why?
|
| Opportunistic Infections | 1 | 2011 | 58 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2013 | 258 | 0.090 |
Why?
|
| Deoxycytidine | 1 | 2011 | 28 | 0.090 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2011 | 74 | 0.090 |
Why?
|
| Fluorouracil | 1 | 2011 | 55 | 0.090 |
Why?
|
| Genes, BRCA1 | 1 | 2011 | 19 | 0.090 |
Why?
|
| Phthalazines | 1 | 2011 | 20 | 0.090 |
Why?
|
| Drugs, Generic | 1 | 2010 | 6 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2013 | 630 | 0.090 |
Why?
|
| Taxoids | 1 | 2010 | 37 | 0.090 |
Why?
|
| Tamoxifen | 1 | 2010 | 59 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2010 | 49 | 0.090 |
Why?
|
| Piperazines | 1 | 2011 | 118 | 0.090 |
Why?
|
| Captopril | 1 | 2009 | 13 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2009 | 74 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 96 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2015 | 121 | 0.080 |
Why?
|
| Enzyme Activation | 1 | 2009 | 270 | 0.080 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2009 | 131 | 0.080 |
Why?
|
| Aorta | 1 | 2009 | 162 | 0.070 |
Why?
|
| Ventricular Function, Left | 1 | 2009 | 158 | 0.070 |
Why?
|
| Age Factors | 1 | 2011 | 1096 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 2188 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 392 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1581 | 0.060 |
Why?
|
| Apoptosis | 1 | 2010 | 1093 | 0.060 |
Why?
|
| Mutation | 1 | 2011 | 1288 | 0.060 |
Why?
|
| Allergy and Immunology | 1 | 2024 | 19 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2013 | 5203 | 0.060 |
Why?
|
| Heart Failure | 1 | 2009 | 508 | 0.050 |
Why?
|
| Respiration | 1 | 2023 | 100 | 0.050 |
Why?
|
| Tracheostomy | 1 | 2023 | 71 | 0.050 |
Why?
|
| Rats | 1 | 2009 | 3277 | 0.050 |
Why?
|
| Animals | 2 | 2022 | 13141 | 0.050 |
Why?
|
| Stem Cells | 1 | 2022 | 171 | 0.050 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 482 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2022 | 210 | 0.040 |
Why?
|
| Hospitalization | 1 | 2024 | 665 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2022 | 648 | 0.040 |
Why?
|
| Arkansas | 1 | 2024 | 1988 | 0.040 |
Why?
|
| Infant | 1 | 2024 | 3584 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2015 | 88 | 0.030 |
Why?
|
| Aged | 3 | 2013 | 9505 | 0.030 |
Why?
|
| United States | 1 | 2024 | 4898 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 269 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 450 | 0.030 |
Why?
|
| Mice | 1 | 2022 | 5673 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2010 | 33 | 0.020 |
Why?
|
| Arthralgia | 1 | 2010 | 43 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 369 | 0.020 |
Why?
|
| Middle Aged | 2 | 2013 | 12356 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 3644 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 3158 | 0.020 |
Why?
|